Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content

Rhea-AI Summary

Safety Shot, Inc. (Nasdaq: SHOT) has announced significant findings from a recent clinical trial conducted at The Center for Applied Health Sciences. The study evaluated the impact of Safety Shot on Blood Alcohol Content (BAC) and demonstrated remarkable results. Within 30 minutes of consuming Safety Shot, participants showed a 30%-50% faster rate of alcohol reduction compared to the placebo group.

Key findings include:

• Consistent lowering of breath alcohol content
• Significant improvements in BAC, ethanol, acetaldehyde, and aldehyde dehydrogenase levels
• Reduced head discomfort, fatigue, and improved concentration

The study results are being prepared for peer review and publication in a biomedical journal. Safety Shot aims to revolutionize the wellness space with its innovative approach to responsible alcohol consumption.

Positive

• Clinical trial demonstrated 30%-50% faster alcohol reduction rate compared to placebo
• Consistent lowering of breath alcohol content at all measured time points
• Significant improvements in BAC, ethanol, acetaldehyde, and aldehyde dehydrogenase levels
• Participants reported reduced head discomfort, fatigue, and improved concentration
• Study results being prepared for peer review and publication in a biomedical journal

Negative

• None.

Insights

Medical Research Analyst

The clinical trial results for Safety Shot are promising, demonstrating a 30%-50% faster reduction in Blood Alcohol Content (BAC) compared to placebo. This is a significant finding in the field of alcohol metabolism. The double-blind, randomized, placebo-controlled study design adds credibility to the results.

However, it's important to note that while the product may aid in faster alcohol clearance, it doesn't negate the effects of alcohol consumption. The long-term safety and potential interactions with medications remain unknown. Further peer-reviewed studies and FDA evaluation will be necessary to fully validate these claims and understand the product's broader implications for public health and safety.

Financial Analyst

This news could have a positive impact on Safety Shot, Inc. (Nasdaq: SHOT). The successful clinical trial results provide a strong foundation for the company's unique product in the wellness and dietary supplement market. If the product gains traction, it could open up a new market segment with significant revenue potential.

However, investors should consider several factors:

• Regulatory approval process and timeline
• Production scalability and costs
• Potential competition and market adoption rates

The company's ability to capitalize on these results and navigate regulatory hurdles will be important for its financial performance. Keep an eye on upcoming quarterly reports for indications of market penetration and revenue growth.

Market Research Analyst

Safety Shot's clinical trial results could disrupt the alcohol consumption market. With increasing health consciousness among consumers, a product that potentially reduces alcohol's negative effects could gain significant traction. The wellness and functional beverage sectors are experiencing rapid growth and Safety Shot is well-positioned to capitalize on this trend.

However, market adoption may face challenges:

• Consumer education on proper use
• Potential misuse as a "quick fix" for excessive drinking
• Regulatory scrutiny and marketing restrictions

The company's marketing strategy and ability to navigate these challenges will be critical for success. Partnerships with bars, restaurants and rideshare companies could provide interesting avenues for growth and market penetration.

First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand’s dietary supplement’s ability to significantly reduce Blood Alcohol Content

JUPITER, FL, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company”), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences (“CAHS”). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer’s Blood Alcohol Content (“BAC”), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.

The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot’s proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world’s first formula to aid in the rapid reduction of alcohol within the body.

“This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials” said Chief Operations Officer and co-inventor, David Sandler. “These results are revolutionizing the wellness space as we continue to pioneer the world’s most innovative functional beverages,” continued Sandler.

Key Findings:

• Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
• Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
• Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.

These groundbreaking findings indicate Safety Shot’s efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study’s results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.

Dr. Tim Ziegenfuss, CEO of CAHS stated, “These results are highly encouraging, showcasing Safety Shot’s potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption.”

For more information about Safety Shot and the full details of the study, please visit www.drinksafetyshot.com.

About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.

About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

Media and Investor Contact:

Autumn Communications
Jess Weinberger
Phone: 201-213-3239
Email: shot@autumncommunications.com

Investor Relations
Medon Michaelides
Phone: 561-244-7100
Email: investors@drinksafetyshot.com 

FAQ

What were the key findings of Safety Shot's clinical trial?

The clinical trial found that Safety Shot reduced Blood Alcohol Content (BAC) 30%-50% faster than the placebo, consistently lowered breath alcohol content, and improved BAC, ethanol, acetaldehyde, and aldehyde dehydrogenase levels. Participants also reported reduced head discomfort, fatigue, and improved concentration.

How quickly does Safety Shot (SHOT) reduce Blood Alcohol Content?

According to the clinical trial, Safety Shot demonstrated a significant drop in Blood Alcohol Content (BAC) within 30 minutes of consumption, with participants showing a 30%-50% faster rate of alcohol reduction compared to the placebo group.

What age group and weight range were included in Safety Shot's clinical trial?

The clinical trial for Safety Shot included participants between the ages of 24 and 46, with bodyweight ranging between 95 and 225 lbs.

Will the results of Safety Shot's (SHOT) clinical trial be published?

Yes, the study results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.